Spotlight on Gynecology/Obstetrics
Gynecology/Obstetrics Presentations
Managing Cardiovascular Disease Risk in Women
StartActivity Details
ABIM MOC
Expires: September 29, 2021
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is gynecologists, obstetricians, family practice physicians, internists, and other health care professionals involved in the management of patients at risk for cardiovascular disease (CVD).
Learning Objectives
Upon successful completion of this activity, participants should be better able to:
- Describe traditional and female-predominant factors that contribute to CVD risk in women.
- Outline available screening tools and guidelines to identify women with elevated CVD risk.
- Review available clinical evidence to select treatment for patients who may benefit from reduction of LDL cholesterol for decreased risk of adverse CVD outcomes.
- Assess evidence-based strategies to reduce triglyceride levels in patients who may benefit from further CVD risk reduction.
- Define approaches to improve patient communication and education to increase awareness of CVD risks in women and the importance of interventions to reduce risk.
Activity Description
Cardiovascular disease is the leading cause of death globally, and women are disproportionately affected, with higher morbidity and mortality rates than men. This trend has continued despite recent advances in awareness campaigns, gender-based guidelines, as well as available therapies. In the United States, CVD accounts for approximately 1 of every 5 female deaths, with almost 300,000 deaths in women each year. In addition to traditional cardiovascular risk factors, women often carry several nontraditional risk factors, many of which are related to pregnancy, hormonal influences, or comorbid disorders. Furthermore, women are less likely to receive guideline-recommended diagnostic testing and therapies. The faculty of this CME activity will address CVD risk factors, appropriate screening, as well as recent advances in management to improve outcomes and reduce CVD mortality.
Agenda
Defining and Recognizing Cardiovascular Disease Risk in Women
Martha Gulati, MD, MS, FACC, FAHA, FASPC
Reducing ASCVD Risk With Further Advances in Lipid-Lowering Therapy
Erin D. Michos, MD, MHS, FACC, FAHA, FASE, FASPC
Clinical Cases
Martha Gulati, MD, MS, FACC, FAHA, FASPC, and Erin D. Michos, MD, MHS, FACC,
FAHA, FASE, FASPC
Faculty
Activity Co-Chairs:
Professor of Medicine
Chief of Cardiology, University of Arizona College of Medicine – Phoenix
Editor-in-Chief, CardioSmart for the American College of Cardiology
Phoenix, AZ
Disclosure: No relevant financial relationships to disclose.
Associate Professor of Medicine & Epidemiology
Director of Women’s Cardiovascular Health
Associate Director of Preventive Cardiology
Ciccarone Center for the Prevention of Cardiovascular Disease
Johns Hopkins University School of Medicine
Baltimore, MD
Disclosure: No relevant financial relationships to disclose.
Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.
Ronald A. Codario, Jr., MD
Disclosure: No relevant financial relationships to disclose.
Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.
Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, faculty, and reviewers involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears above which is accurate at the time of content development.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this
CME activity, which includes participation in the evaluation component,
enables the participant to earn up to 1.25 Medical Knowledge Maintenance of
Certification (MOC) points in the American Board of Internal Medicine's
(ABIM) MOC program. It is the CME activity provider's responsibility to
submit participant completion information to ACCME for the purpose of
granting ABIM MOC credit.
Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 80% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Statement of Commercial Support
This activity is supported by an educational grant from Amarin Pharma Inc.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com
Activity Details
ABIM MOC
Expires: September 29, 2021
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is gynecologists, obstetricians, family practice physicians, internists, and other health care professionals involved in the management of patients at risk for cardiovascular disease (CVD).
Learning Objectives
Upon successful completion of this activity, participants should be better able to:
- Describe traditional and female-predominant factors that contribute to CVD risk in women.
- Outline available screening tools and guidelines to identify women with elevated CVD risk.
- Review available clinical evidence to select treatment for patients who may benefit from reduction of LDL cholesterol for decreased risk of adverse CVD outcomes.
- Assess evidence-based strategies to reduce triglyceride levels in patients who may benefit from further CVD risk reduction.
- Define approaches to improve patient communication and education to increase awareness of CVD risks in women and the importance of interventions to reduce risk.
Activity Description
Cardiovascular disease is the leading cause of death globally, and women are disproportionately affected, with higher morbidity and mortality rates than men. This trend has continued despite recent advances in awareness campaigns, gender-based guidelines, as well as available therapies. In the United States, CVD accounts for approximately 1 of every 5 female deaths, with almost 300,000 deaths in women each year. In addition to traditional cardiovascular risk factors, women often carry several nontraditional risk factors, many of which are related to pregnancy, hormonal influences, or comorbid disorders. Furthermore, women are less likely to receive guideline-recommended diagnostic testing and therapies. The faculty of this CME activity will address CVD risk factors, appropriate screening, as well as recent advances in management to improve outcomes and reduce CVD mortality.
Agenda
Defining and Recognizing Cardiovascular Disease Risk in Women
Martha Gulati, MD, MS, FACC, FAHA, FASPC
Reducing ASCVD Risk With Further Advances in Lipid-Lowering Therapy
Erin D. Michos, MD, MHS, FACC, FAHA, FASE, FASPC
Clinical Cases
Martha Gulati, MD, MS, FACC, FAHA, FASPC, and Erin D. Michos, MD, MHS, FACC,
FAHA, FASE, FASPC
Faculty
Activity Co-Chairs:
Professor of Medicine
Chief of Cardiology, University of Arizona College of Medicine – Phoenix
Editor-in-Chief, CardioSmart for the American College of Cardiology
Phoenix, AZ
Disclosure: No relevant financial relationships to disclose.
Associate Professor of Medicine & Epidemiology
Director of Women’s Cardiovascular Health
Associate Director of Preventive Cardiology
Ciccarone Center for the Prevention of Cardiovascular Disease
Johns Hopkins University School of Medicine
Baltimore, MD
Disclosure: No relevant financial relationships to disclose.
Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.
Ronald A. Codario, Jr., MD
Disclosure: No relevant financial relationships to disclose.
Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.
Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, faculty, and reviewers involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears above which is accurate at the time of content development.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this
CME activity, which includes participation in the evaluation component,
enables the participant to earn up to 1.25 Medical Knowledge Maintenance of
Certification (MOC) points in the American Board of Internal Medicine's
(ABIM) MOC program. It is the CME activity provider's responsibility to
submit participant completion information to ACCME for the purpose of
granting ABIM MOC credit.
Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 80% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Statement of Commercial Support
This activity is supported by an educational grant from Amarin Pharma Inc.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com
Incorporating Recently Approved Targeted Agents, Emerging Combinations, and Genetic Testing for the Optimal Management of Patients with Ovarian Cancer
StartActivity Details
Expires: April 18, 2021
Accredited By
The University of Nebraska Medical Center, Center for Continuing Education
Target Audience
The target audience for this activity is gynecologic oncologists, medical oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with gynecologic malignancies.
Learning Objectives
After participating in this activity, participants should be better able to:
- Assess the efficacy and safety of PARP inhibitors or their combinations in the maintenance and treatment setting for the management of patients with ovarian cancer
- Evaluate the various genetic testing platforms and their utility in identifying appropriate patients for platinum-based therapy and PARP inhibitor therapy
- Develop strategies for the optimal utilization of PARP inhibitors when managing patients with ovarian cancer
- Review novel agents that are under investigation for the treatment of platinum-resistant ovarian cancer
Activity Description
This activity will provide expert guidance regarding the use of currently-available therapies and companion diagnostics and will help clinicians plan for the optimal integration of new indications and combinations into practice when they become available.
Statement of Educational Need
Considering the volume of research regarding the use of PARP inhibitors for patients with ovarian cancer, clinicians are challenged to evaluate and interpret the clinical significance of emerging data, both scientific and clinical. Thus, clinicians treating patients with ovarian cancer need expert guidance to evaluate emerging scientific and clinical data, use existing PARP inhibitors safely and effectively, and plan strategies to appropriately integrate new indications and combinations into practice when they become available, in consideration of patient needs and preferences.
Agenda
- Currently Available Systemic and Maintenance Therapies and Emerging Combinations for the Treatment of Ovarian Cancer
- Integrating Genetic Testing Into Clinical Practice
- Real-World Use of Poly ADP Ribose Polymerase Inhibitors (PARPi): Case-Based Discussion
- Summary
Faculty
Deputy Director, University of Cincinnati Cancer Institute
Paul & Carolyn Flory Professor, Vice-Chair of Quality & Safety
Department of Obstetrics & Gynecology
University of Cincinnati
Cincinnati, Ohio
Disclosures
Advisory Boards: AstraZeneca, Caris Life Sciences, Clovis Oncology, F. Hoffman-La Roche, Tesaro, Inc.
Conflict of Interest Policy/Disclosure Statement
Faculty and Planning Committee Disclosures
As a provider accredited by ACCME, the UNMC Center for Continuing Education must ensure balance, objectivity, independence, and scientific rigor in its educational activities. Presenters are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or the trade names of several to ensure impartiality.
All presenters, planners, and others in a position to control continuing medical education content participating in a UNMC Center for Continuing Education activity are required to disclose relationships with commercial interests. A commercial interest is any entity producing, marketing, reselling, or distributing health care goods or services consumed by, or used on, patients. Disclosure of these commitments and/or relationships is included in activity materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations.
This activity may include presentations in which presenters may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications.
All materials are included with the permission of the authors. The opinions expressed are those of the authors and are not to be construed as those of the UNMC Center for Continuing Education or Bio Ascend. The information presented in this activity is not meant to serve as a guideline for patient management; primary references, relevant practice guidelines, and full prescribing information should be consulted.
The faculty and planning committee members for this activity have no conflicts to disclose with the exception of those listed on the following presenter slide. All disclosed conflicts of interest have been resolved by independent content review.
Accreditation Statement
Continuing Education
The University of Nebraska Medical Center (UNMC) Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The UNMC Center for Continuing Education designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the ACCME through the joint providership of the UNMC Center for Continuing Education and Bio Ascend.
Instructions for Receiving Credit
There are no fees for participating and receiving credit for this activity. During the accredited period, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-activity assessments and evaluation.
Participants who complete the educational activity, pre- and post-activity assessments, and evaluation will receive a certificate of credit.
Materials will be available online through April 18, 2021.
Statement of Commercial Support
This activity is supported by independent educational grants from AstraZeneca, Clovis Oncology, and Tesaro, a GSK Company.
Disclaimer Statement/Disclosure of Unlabeled Use
UNMC CCE and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of UNMC CCE and Bio Ascend.
Contact Information for Questions About the Activity
cme@bioascend.com
Activity Details
Expires: April 18, 2021
Accredited By
The University of Nebraska Medical Center, Center for Continuing Education
Target Audience
The target audience for this activity is gynecologic oncologists, medical oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with gynecologic malignancies.
Learning Objectives
After participating in this activity, participants should be better able to:
- Assess the efficacy and safety of PARP inhibitors or their combinations in the maintenance and treatment setting for the management of patients with ovarian cancer
- Evaluate the various genetic testing platforms and their utility in identifying appropriate patients for platinum-based therapy and PARP inhibitor therapy
- Develop strategies for the optimal utilization of PARP inhibitors when managing patients with ovarian cancer
- Review novel agents that are under investigation for the treatment of platinum-resistant ovarian cancer
Activity Description
This activity will provide expert guidance regarding the use of currently-available therapies and companion diagnostics and will help clinicians plan for the optimal integration of new indications and combinations into practice when they become available.
Statement of Educational Need
Considering the volume of research regarding the use of PARP inhibitors for patients with ovarian cancer, clinicians are challenged to evaluate and interpret the clinical significance of emerging data, both scientific and clinical. Thus, clinicians treating patients with ovarian cancer need expert guidance to evaluate emerging scientific and clinical data, use existing PARP inhibitors safely and effectively, and plan strategies to appropriately integrate new indications and combinations into practice when they become available, in consideration of patient needs and preferences.
Agenda
- Currently Available Systemic and Maintenance Therapies and Emerging Combinations for the Treatment of Ovarian Cancer
- Integrating Genetic Testing Into Clinical Practice
- Real-World Use of Poly ADP Ribose Polymerase Inhibitors (PARPi): Case-Based Discussion
- Summary
Faculty
Deputy Director, University of Cincinnati Cancer Institute
Paul & Carolyn Flory Professor, Vice-Chair of Quality & Safety
Department of Obstetrics & Gynecology
University of Cincinnati
Cincinnati, Ohio
Disclosures
Advisory Boards: AstraZeneca, Caris Life Sciences, Clovis Oncology, F. Hoffman-La Roche, Tesaro, Inc.
Conflict of Interest Policy/Disclosure Statement
Faculty and Planning Committee Disclosures
As a provider accredited by ACCME, the UNMC Center for Continuing Education must ensure balance, objectivity, independence, and scientific rigor in its educational activities. Presenters are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or the trade names of several to ensure impartiality.
All presenters, planners, and others in a position to control continuing medical education content participating in a UNMC Center for Continuing Education activity are required to disclose relationships with commercial interests. A commercial interest is any entity producing, marketing, reselling, or distributing health care goods or services consumed by, or used on, patients. Disclosure of these commitments and/or relationships is included in activity materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations.
This activity may include presentations in which presenters may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications.
All materials are included with the permission of the authors. The opinions expressed are those of the authors and are not to be construed as those of the UNMC Center for Continuing Education or Bio Ascend. The information presented in this activity is not meant to serve as a guideline for patient management; primary references, relevant practice guidelines, and full prescribing information should be consulted.
The faculty and planning committee members for this activity have no conflicts to disclose with the exception of those listed on the following presenter slide. All disclosed conflicts of interest have been resolved by independent content review.
Accreditation Statement
Continuing Education
The University of Nebraska Medical Center (UNMC) Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The UNMC Center for Continuing Education designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the ACCME through the joint providership of the UNMC Center for Continuing Education and Bio Ascend.
Instructions for Receiving Credit
There are no fees for participating and receiving credit for this activity. During the accredited period, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-activity assessments and evaluation.
Participants who complete the educational activity, pre- and post-activity assessments, and evaluation will receive a certificate of credit.
Materials will be available online through April 18, 2021.
Statement of Commercial Support
This activity is supported by independent educational grants from AstraZeneca, Clovis Oncology, and Tesaro, a GSK Company.
Disclaimer Statement/Disclosure of Unlabeled Use
UNMC CCE and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of UNMC CCE and Bio Ascend.
Contact Information for Questions About the Activity
cme@bioascend.com